显示样式:     当前期刊: European Heart Journal    加入关注    导出
我的关注
我的收藏
您暂时未登录!
登录
  • Prognostic impacts of Rho-kinase activity in circulating leucocytes in patients with vasospastic angina
    Eur. Heart J. (IF 19.651) Pub Date : 2017-11-20
    Taro Nihei, Jun Takahashi, Kiyotaka Hao, Yoku Kikuchi, Yuji Odaka, Ryuji Tsuburaya, Kensuke Nishimiya, Yasuharu Matsumoto, Kenta Ito, Satoshi Miyata, Yasuhiko Sakata, Hiroaki Shimokawa

    Rho-kinase activity in circulating leucocytes is a useful biomarker for diagnosis and disease activity assessment of vasospastic angina (VSA). The present study aimed to examine the long-term prognostic impact of Rho-kinase activity in circulating leucocytes in VSA patients.

    更新日期:2017-11-20
  • Affairs of the heart: outcomes in men and women with hypertrophic cardiomyopathy
    Eur. Heart J. (IF 19.651) Pub Date : 2017-11-20
    Constantinos O’Mahony, Perry Elliott

    This editorial refers to ‘Women with hypertrophic cardiomyopathy have worse survival’, by J.B. Geske et al., doi: 10.1093/eurheartj/ehx527.

    更新日期:2017-11-20
  • Lamin A/C mutations in patients with dilated cardiomyopathy
    Eur. Heart J. (IF 19.651) Pub Date : 2017-11-20
    Sabine Pankuweit

    This editorial refers to ‘Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantations’, by N.E. Hasselberg et al., doi: 10.1093/eurheartj/ehx596.

    更新日期:2017-11-20
  • Resumption of oral anticoagulation following traumatic injury and risk of stroke and bleeding in patients with atrial fibrillation: a nationwide cohort study
    Eur. Heart J. (IF 19.651) Pub Date : 2017-11-18
    Laila Staerk, Emil Loldrup Fosbøl, Morten Lamberts, Anders Nissen Bonde, Kasper Gadsbøll, Caroline Sindet-Pedersen, Ellen A Holm, Thomas Alexander Gerds, Brice Ozenne, Gregory Y H Lip, Christian Torp-Pedersen, Gunnar Hilmar Gislason, Jonas Bjerring Olesen

    We examined the risks of all-cause mortality, stroke, major bleeding, and recurrent traumatic injury associated with resumption of vitamin K antagonists (VKAs) and non-VKAs oral anticoagulants (NOACs) following traumatic injury in atrial fibrillation (AF) patients.

    更新日期:2017-11-19
  • The effect of 1.5 T cardiac magnetic resonance on human circulating leucocytes
    Eur. Heart J. (IF 19.651) Pub Date : 2017-11-18
    William R Critchley, Anna Reid, Julie Morris, Josephine H Naish, John P Stone, Alexandra L Ball, Triin Major, David Clark, Nick Waldron, Christien Fortune, Jakub Lagan, Gavin A Lewis, Mark Ainslie, Erik B Schelbert, Daniel M Davis, Matthias Schmitt, James E Fildes, Christopher A Miller

    Investigators have proposed that cardiovascular magnetic resonance (CMR) should have restrictions similar to those of ionizing imaging techniques. We aimed to investigate the acute effect of 1.5 T CMR on leucocyte DNA integrity, cell counts, and function in vitro, and in a large cohort of patients in vivo.

    更新日期:2017-11-19
  • Quantifying infective endocarditis risk in patients with predisposing cardiac conditions
    Eur. Heart J. (IF 19.651) Pub Date : 2017-11-17
    Martin H Thornhill, Simon Jones, Bernard Prendergast, Larry M Baddour, John B Chambers, Peter B Lockhart, Mark J Dayer

    There are scant comparative data quantifying the risk of infective endocarditis (IE) and associated mortality in individuals with predisposing cardiac conditions.

    更新日期:2017-11-17
  • The challenges of antithrombotic therapy in patients with left ventricular thrombosis
    Eur. Heart J. (IF 19.651) Pub Date : 2017-11-17
    Wael Sumaya, Robert F Storey

    This editorial refers to ‘Anticoagulation combined with antiplatelet therapy in patients with left ventricular thrombus after first acute myocardial infarctions’, by N. Maniwa et al., doi: 10.1093/eurheartj/ehx551.

    更新日期:2017-11-17
  • Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes
    Eur. Heart J. (IF 19.651) Pub Date : 2017-11-16
    Roland Klingenberg, Soheila Aghlmandi, Christoph Liebetrau, Lorenz Räber, Baris Gencer, David Nanchen, David Carballo, Alexander Akhmedov, Fabrizio Montecucco, Stefan Zoller, Chad Brokopp, Dik Heg, Peter Jüni, Helena Marti Soler, Pedro-Manuel Marques-Vidal, Peter Vollenweider, Oliver Dörr, Nicolas Rodondi, François Mach, Stephan Windecker, Ulf Landmesser, Arnold von Eckardstein, Christian W Hamm, Christian M Matter, Thomas F Lüscher

    We aimed to identify a novel biomarker involved in the early events leading to an acute coronary syndrome (ACS) and evaluate its role in diagnosis and risk stratification.

    更新日期:2017-11-17
  • Rare coronary anomaly with hemodynamic consequence: squeezing of the right coronary artery
    Eur. Heart J. (IF 19.651) Pub Date : 2017-11-13
    Andrea Denegri, Nooraldaem Yousif, Robert Manka, Hatem Alkadhi, Willibald Maier

    A 61-year-old hypertensive woman, known for seronegative arthritis under immunosuppressive therapy, was admitted to our department for dyspnea New York Heart Association Class II, angina and a positive stress cardiac-magnetic resonance imaging (MRI) showing an anteroseptal and inferoseptal inducible ischaemia (PanelsA: rest and B: stress). Physical examination was unremarkable and laboratory values figured out a mild hypercholesterolaemia. The coronary anatomy at angiography showed a tiny, rudimentary vessel arising from the ostium of the right coronary artery (RCA) and no significant narrowing of the left coronary artery (LCA). However, the branching pattern of the LCA did not correspond to typical left dominance. Instead, a branch traversing the septum and subjected to systolic compression appeared to supply the inferobasal septum and most of the usual perfusion...

    更新日期:2017-11-17
  • Annular rupture during transcatheter aortic valve replacement: novel treatment with amplatzer vascular plugs
    Eur. Heart J. (IF 19.651) Pub Date : 2017-11-13
    Mohamad Alkhouli, Elizabeth Carpenter, Abdul Tarabishy, Partho Sengupta

    A 84-year-old woman was referred for transcatheter aortic valve replacement. Computed tomography showed an annular area of 429 mm2, with a focal calcified annular nodule. Therefore, transfemoral implantation of a 23 mm Sapien S3 valve (Edwards, Irvine, CA, USA) was planned (the recommended annular area for 23 mm valve is 338–430 mm2). Post valve deployment, a mild–moderate paravalvular leak was seen, and the valve was therefore post-dilated with an additional 1 cc of diluted contrast, ameliorating the leak (see Supplementary material online, VideoS1). Following percutaneous access closure, the patient developed sudden hypotension due to cardiac tamponade. Emergent pericardiocentesis retrieved 1 L of bloody effusion. Aortic root angiogram, performed via right radial access, revealed an annular rupture with active bleeding into the pericardium...

    更新日期:2017-11-17
  • Cholesterol variability: a marker for increased risk or a risk factor?
    Eur. Heart J. (IF 19.651) Pub Date : 2017-11-13
    Sripal Bangalore

    This editorial refers to ‘Cholesterol variability and the risk of mortality, myocardial infarction, and stroke: a nationwide population-based study’, by M.K. Kim et al., doi: 10.1093/eurheartj/ehx585.

    更新日期:2017-11-17
  • The ABC death risk score: is it time to start measuring GDF-15?
    Eur. Heart J. (IF 19.651) Pub Date : 2017-11-10
    M Benjamin Shoemaker, William G Stevenson

    This editorial refers to ‘A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score’, by Z. Hijazi et al., doi: 10.1093/eurheartj/ehx584.

    更新日期:2017-11-17
  • Asymptomatic dissection of a giant aorta ascendens aneurysm in Turner syndrome
    Eur. Heart J. (IF 19.651) Pub Date : 2017-11-10
    Piotr Dobrowolski, Anna Klisiewicz, Ilona Michałowska, Mariusz Kuśmierczyk, Piotr Hoffman

    Turner syndrome (TS) is a chromosomal disorder that affects 1:2000 women. Clinical features of TS include short stature, delayed puberty and congenital cardiac malformations. Turner syndrome patients have an increased prevalence of cardiometabolic risk factors, which predisposes them to complications like coronary artery disease, cerebrovascular-related deaths and aortic dissection. We present, a 35-year-old asymptomatic woman with TS who was referred to our institution because of dilatation of the ascending aorta. Laboratory assessment revealed an increased level of N-terminal pro B-type natriuretic peptide (NT-proBNP; 1510 pg/mL) and anaemia. The chest X-ray showed a widening of the mediastinum (Panel A). Transthoracic echocardiographic study showed giant ascending aortic aneurysm (92 mm) (Panel B) with dissection (see arrow in Panel B). Additionally, severe aortic stenosis (Vmax...

    更新日期:2017-11-17
  • Calcific aortic valve stenosis: hard disease in the heart: A biomolecular approach towards diagnosis and treatment
    Eur. Heart J. (IF 19.651) Pub Date : 2017-11-10
    Frederique E C M Peeters, Steven J R Meex, Marc R Dweck, Elena Aikawa, Harry J G M Crijns, Leon J Schurgers, Bas L J H Kietselaer

    Calcific aortic valve stenosis (CAVS) is common in the ageing population and set to become an increasing economic and health burden. Once present, it inevitably progresses and has a poor prognosis in symptomatic patients. No medical therapies are proven to be effective in holding or reducing disease progression. Therefore, aortic valve replacement remains the only available treatment option. Improved knowledge of the mechanisms underlying disease progression has provided us with insights that CAVS is not a passive disease. Rather, CAVS is regulated by numerous mechanisms with a key role for calcification. Aortic valve calcification (AVC) is actively regulated involving cellular and humoral factors that may offer targets for diagnosis and intervention. The discovery that the vitamin K-dependent proteins are involved in the inhibition of AVC has boosted our mechanistic understanding of this process and has opened up novel avenues in disease exploration. This review discusses processes involved in CAVS progression, with an emphasis on recent insights into calcification, methods for imaging calcification activity, and potential therapeutic options.

    更新日期:2017-11-17
  • A battle in the crusade to understand scimitar syndrome
    Eur. Heart J. (IF 19.651) Pub Date : 2017-11-10
    Alexander R Opotowsky, Gary D Webb

    This editorial refers to ‘The natural history and surgical outcome of patients with scimitar syndrome: a multi-centre European study’, by V.L. Vida et al., doi: 10.1093/eurheartj/ehx526.

    更新日期:2017-11-17
  • The forkhead transcription factor Foxo3 negatively regulates natural killer cell function and viral clearance in myocarditis
    Eur. Heart J. (IF 19.651) Pub Date : 2017-11-09
    Madlen Loebel, Luise Holzhauser, Jelka A Hartwig, Praphulla C Shukla, Konstantinos Savvatis, Alexander Jenke, Martina Gast, Felicitas Escher, Sonya C Becker, Sandra Bauer, Andrea Stroux, Antje Beling, Meike Kespohl, Sandra Pinkert, Henry Fechner, Uwe Kuehl, Dirk Lassner, Wolfgang Poller, Heinz-Peter Schultheiss, Tanja Zeller, Stefan Blankenberg, Anna-Pia Papageorgiou, Stephane Heymans, Ulf Landmesser, Carmen Scheibenbogen, Carsten Skurk

    Foxo3 is a transcription factor involved in cell metabolism, survival, and inflammatory disease. However, mechanistic insight in Foxo3 effects is still limited. Here, we investigated the role of Foxo3 on natural killer (NK) cell responses and its effects in viral myocarditis.

    更新日期:2017-11-17
  • Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
    Eur. Heart J. (IF 19.651) Pub Date : 2017-11-08
    Alexander Niessner, Juan Tamargo, Lorenz Koller, Christoph H Saely, Thomas Andersen Schmidt, Gianluigi Savarese, Sven Wassmann, Giuseppe Rosano, Claudio Ceconi, Christian Torp-Pedersen, Juan Carlos Kaski, Keld Per Kjeldsen, Stefan Agewall, Thomas Walther, Heinz Drexel, Basil S Lewis

    Patients with type 2 diabetes mellitus (T2DM) and established cardiovascular disease (CVD) have a particularly high risk for recurrent major adverse cardiovascular events (MACE).1 Compared with patients with CVD only, the risk for MACE increases by about 1.7-fold in those with CVD and T2DM.1 Type 2 diabetes mellitus is a stronger risk factor for MACE than the angiographic severity of coronary heart disease (CHD).2 Reducing the T2DM-associated risk is therefore of utmost importance. Antidiabetic pharmacotherapy reduces plasma glucose and dosing is adjusted according to HbA1c concentration. European Society of Cardiology (ESC) guidelines recommend HbA1c values <7% for patients with CVD.3 While controlling HbA1c levels is important to prevent both microvascular disease and atherosclerosis progression, the association between HbA1c and short to mid-term cardiovascular events is...

    更新日期:2017-11-17
  • First-in-man implantation of a pre-packaged self-expandable dry-tissue transcatheter aortic valve
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-31
    Yuan Feng, Zhen-Gang Zhao, Jorge Baccaro, Min Frank Zeng, R David Fish, Mao Chen

    Transcatheter aortic valve implantation (TAVI) has become the mainstay of treatment for aortic stenosis. Reasonable extension of TAVI utilization into a broader group, however, would mandate further device refinement.

    更新日期:2017-11-17
  • Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-31
    Nina Eide Hasselberg, Trine Fink Haland, Jørg Saberniak, Pål Haugar Brekke, Knut Erik Berge, Trond Paul Leren, Thor Edvardsen, Kristina Hermann Haugaa

    Lamin A/C (LMNA) mutations cause familial dilated cardiomyopathy (DCM) with frequent conduction blocks and arrhythmias. We explored the prevalence, cardiac penetrance, and expressivity of LMNA mutations among familial DCM in Norway. Furthermore, we explored the risk factors and the outcomes in LMNA patients.

    更新日期:2017-11-17
  • Diagnosis of active pericarditis by positron emission tomography (PET)/cardiac magnetic resonance (CMR) imaging
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-31
    Bo Xu, Steve Shih-Lin Huang, Christine Jellis, Scott D Flamm

    We describe the first reported case of active pericarditis diagnosed by positron emission tomography (PET) and cardiac magnetic resonance (CMR) fusion imaging.

    更新日期:2017-11-17
  • Corrigendum
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-30

    Corrigendum to: Clinical implication of an impaired fasting glucose and prehypertension related to new onset atrial fibrillation in a healthy Asian population without underlying disease: a nationwide cohort study in Korea [Eur Heart J (2017); 38 (34): 2599–2607].

    更新日期:2017-11-17
  • Embolic protection for tricuspid valve-in-valve intervention
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-28
    Fabien Praz, Isaac George, Omar K Khalique, Susheel K Kodali

    A 41-year-old woman known for Ebstein’s anomaly was admitted to the hospital for acute hypoxic respiratory distress (New York Heart Association Class IV). A transoesophageal echocardiogram revealed thickened valve leaflets consistent with valve thrombosis 1 year after surgical placement of a 33-mm St. Jude Epic bioprosthesis for treatment of severe tricuspid regurgitation (Panel A). Restricted excursion of the valve leaflets resulted in a decreased effective orifice area of 0.63 cm2 by transoesophageal echocardiography (Panel B). Percutaneous tricuspid valve-in-valve implantation was planned as a bridge to repeat valve surgery. There was an associated small atrial septal defect (ASD) (5 mm) with right-to-left shunting (Panel C). Because of the large thrombus burden and the risk of paradoxical embolism through the ASD, temporary Doppler-controlled occlusion...

    更新日期:2017-11-17
  • First in human transcatheter COMBO mitral valve repair with direct ring annuloplasty and neochord leaflet implantation to treat degenerative mitral regurgitation: feasibility of the simultaneous toolbox concept guided by 3D echo and computed tomography fusion imaging
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-27
    Ralph Stephan von Bardeleben, Andrea Colli, Eberhard Schulz, Tobias Ruf, Krzysztof Wrobel, Christian-Friedrich Vahl, Gino Gerosa, Christian Werner, Thomas Münzel, Andres Beiras-Fernandez

    In mitral valve (MV) prolapse with flail leaflet, the combination of surgical repair including annuloplasty and chordal replacement is the current standard of care. Both valvular heart disease guidelines in the USA and Europe published in 2017 acknowledge a future role of transcatheter approaches in non-low-risk patients. We present here a first in human case of a transvenous transcatheter off-pump direct annuloplasty with the Edwards Cardioband system and simultaneous one-staged transapical off-pump transcatheter implantation of three NeoChordae using the NeoChord DS1000 application system to treat a 63-year-old male with a STS-score of mortality of 8% and a logistic EuroScore of 31%. The patient suffered from severe mitral regurgitation due to a chordal rupture on the P2 segment and annular dilatation (anteroposterior diameter of 42 mm) with a leaflet-to-annulus-index (LAI)...

    更新日期:2017-11-17
  • Corrigendum
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-26

    Corrigendum to: Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials [Eur Heart J (2017); doi:10.1093/eurheartj/ehx363].

    更新日期:2017-11-17
  • Corrigendum
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-26

    Corrigendum to: 2017 ESC/EACTS Guidelines for the management of valvular heart disease [Eur Heart J (2017) 38(36):2739–2786].

    更新日期:2017-11-17
  • Corrigendum
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-26

    Corrigendum to: 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation [Eur Heart J (2017); doi:10.1093/eurheartj/ehx393].

    更新日期:2017-11-17
  • Corrigendum
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-26

    Corrigendum to: 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS [Eur Heart J (2017); doi:10.1093/eurheartj/ehx419].

    更新日期:2017-11-17
  • Predicting the outcome of degenerative mitral regurgitation: a step forward but still a long way to go!
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-25
    Alec Vahanian, Bernard Iung

    This editorial refers to ‘The MIDA mortality risk score: development and external validation of a prognostic model for early and late death in degenerative mitral regurgitation’, by F. Grigioni et al., doi: 10.1093/eurheartj/ehx465.

    更新日期:2017-11-17
  • Minimally invasive intervention of radial artery pseudoaneurysm using percutaneous thrombin injection
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-25
    Homam Moussa Pacha, M Chadi Alraies, Mohamad Soud, Nelson L Bernardo

    A 67-year-old woman with severe mitral regurgitation, underwent coronary angiography for pre-operative evaluation prior to mitral valve surgery via right radial artery (RA) which showed normal coronaries. TR band® was applied for haemostasis; however, a small haematoma developed, and this prompted to keep the TR Band® for a longer period. The following morning, patient complained of right forearm pain. Exam revealed a pulsatile mass over the access site (Supplementary material online, Video S1). Arterial duplex showed a large RA pseudoaneurysm (PSA) emanating from the right RA and measuring 26.5 × 14.4 mm (Panel A and B, Supplementary material online, Video S2). Treatment options were explored including surgical repair. However, patient opted for percutaneous endovascular intervention (PEI) using thrombin injection into...

    更新日期:2017-11-17
  • Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-25
    Sarah Costantino, Francesco Paneni, Agostino Virdis, Shafaat Hussain, Shafeeq Ahmed Mohammed, Giuliana Capretti, Alexander Akhmedov, Kevin Dalgaard, Sergio Chiandotto, J Andrew Pospisilik, Thomas Jenuwein, Marco Giorgio, Massimo Volpe, Stefano Taddei, Thomas F Lüscher, Francesco Cosentino

    Accumulation of reactive oxygen species (ROS) promotes vascular disease in obesity, but the underlying molecular mechanisms remain poorly understood. The adaptor p66Shc is emerging as a key molecule responsible for ROS generation and vascular damage. This study investigates whether epigenetic regulation of p66Shc contributes to obesity-related vascular disease.

    更新日期:2017-11-17
  • Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-24
    Renate M Hoogeveen, Matthias Nahrendorf, Niels P Riksen, Mihai G Netea, Menno P J de Winther, Esther Lutgens, Boerge Nordestgaard, Michel Neidhart, Erik S G Stroes, Alberico L Catapano, Siroon Bekkering

    A large number of cardiovascular events are not prevented by current therapeutic regimens. In search for additional, innovative strategies, immune cells have been recognized as key players contributing to atherosclerotic plaque progression and destabilization. Particularly the role of innate immune cells is of major interest, following the recent paradigm shift that innate immunity, long considered to be incapable of learning, does exhibit immunological memory mediated via epigenetic reprogramming. Compelling evidence shows that atherosclerotic risk factors promote immune cell migration by pre-activation of circulating innate immune cells. Innate immune cell activation via metabolic and epigenetic reprogramming perpetuates a systemic low-grade inflammatory state in cardiovascular disease (CVD) that is also common in other chronic inflammatory disorders. This opens a new therapeutic area in which metabolic or epigenetic modulation of innate immune cells may result in decreased systemic chronic inflammation, alleviating CVD, and its co-morbidities.

    更新日期:2017-11-17
  • A meta-analysis of continuous positive airway pressure therapy in prevention of cardiovascular events in patients with obstructive sleep apnoea
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-24
    Safi U Khan, Crystal A Duran, Hammad Rahman, Manidhar Lekkala, Muhammad A Saleem, Edo Kaluski

    To assess whether continuous positive airway pressure (CPAP) therapy reduces major adverse cardiovascular events (MACE) in patients with moderate-to-severe obstructive sleep apnoea (OSA).

    更新日期:2017-11-17
  • Less dementia with oral anticoagulation in atrial fibrillation
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-24
    Leif Friberg, Mårten Rosenqvist

    The association between atrial fibrillation (AF) and dementia is well documented, but it is not clear if oral anticoagulant treatment offers protection. The aim of the study is therefore to compare the incidence of new dementia in patients with AF with and without oral anticoagulants, and to explore if there is a difference between novel anticoagulants and warfarin in this respect.

    更新日期:2017-11-17
  • Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-23
    Konstantinos C Koskinas, George C M Siontis, Raffaele Piccolo, Dimitris Mavridis, Lorenz Räber, François Mach, Stephan Windecker

    Current evidence on dyslipidaemia management has expanded to novel treatments and very low achieved levels of low-density lipoprotein cholesterol (LDL-C). We sought to compare the clinical impact of more-intensive vs. less-intensive LDL-C lowering by means of statins and currently recommended non-statin medications in secondary prevention.

    更新日期:2017-11-17
  • Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-23
    Sarah Costantino, Peter Libby, Raj Kishore, Jean-Claude Tardif, Assam El-Osta, Francesco Paneni

    Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide and also inflict major burdens on morbidity, quality of life, and societal costs. Considering that CVD preventive medications improve vascular outcomes in less than half of patients (often relative risk reductions range from 12% to 20% compared with placebo), precision medicine offers an attractive approach to refine the targeting of CVD medications to responsive individuals in a population and thus allocate resources more wisely and effectively. New tools furnished by advances in basic science and translational medicine could help achieve this goal. This approach could reach beyond the practitioners ‘eyeball’ assessment or venerable markers derived from the physical examination and standard laboratory evaluation. Advances in genetics have identified novel pathways and targets that operate in numerous diseases, paving the way for ‘precision medicine’. Yet the inherited genome determines only part of an individual’s risk profile. Indeed, standard genomic approaches do not take into account the world of regulation of gene expression by modifications of the ‘epi’genome. Epigenetic modifications defined as ‘heritable changes to the genome that do not involve changes in DNA sequence’ have emerged as a new layer of biological regulation in CVD and could advance individualized risk assessment as well as devising and deploying tailored therapies. This review, therefore, aims to acquaint the cardiovascular community with the rapidly advancing and evolving field of epigenetics and its implications in cardiovascular precision medicine.

    更新日期:2017-11-17
  • Retinal microvascular dysfunction in heart failure
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-21
    Matthias P Nägele, Jens Barthelmes, Valeria Ludovici, Silviya Cantatore, Arnold von Eckardstein, Frank Enseleit, Thomas F Lüscher, Frank Ruschitzka, Isabella Sudano, Andreas J Flammer

    Retinal vessel analysis (RVA) represents a novel, non-invasive, and reliable method to study the microcirculation in the eye. The goal of this study was to assess the extent of retinal microvascular dysfunction in patients with chronic heart failure (CHF) compared to controls and established measures of vascular function.

    更新日期:2017-11-17
  • A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-21
    Ziad Hijazi, Jonas Oldgren, Johan Lindbäck, John H Alexander, Stuart J Connolly, John W Eikelboom, Michael D Ezekowitz, Claes Held, Elaine M Hylek, Renato D Lopes, Salim Yusuf, Christopher B Granger, Agneta Siegbahn, Lars Wallentin

    In atrial fibrillation (AF), mortality remains high despite effective anticoagulation. A model predicting the risk of death in these patients is currently not available. We developed and validated a risk score for death in anticoagulated patients with AF including both clinical information and biomarkers.

    更新日期:2017-11-17
  • Cholesterol variability and the risk of mortality, myocardial infarction, and stroke: a nationwide population-based study
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-21
    Mee Kyoung Kim, Kyungdo Han, Hun-Sung Kim, Yong-Moon Park, Hyuk-Sang Kwon, Kun-Ho Yoon, Seung-Hwan Lee

    A high visit-to-visit variability in cholesterol levels has been suggested to be an independent predictor of major adverse cardiovascular events in patients with coronary artery disease (CAD). Because whether this notion applies to general population is not known, we aimed to investigate the associations between total cholesterol (TC) variability and the risk of all-cause mortality, myocardial infarction (MI), and stroke.

    更新日期:2017-11-17
  • Advantages of sacubitril/valsartan beyond blood pressure control in arterial hypertension
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-20
    Gema Ruiz-Hurtado, Luis M Ruilope

    This editorial refers to ‘The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study’, by R.E. Schmeider et al., doi: 10.1093/eurheartj/ehx525.

    更新日期:2017-11-17
  • Strategies for radiation dose reduction in nuclear cardiology and cardiac computed tomography imaging: a report from the European Association of Cardiovascular Imaging (EACVI), the Cardiovascular Committee of European Association of Nuclear Medicine (EANM), and the European Society of Cardiovascular Radiology (ESCR)
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-20
    Alessia Gimelli, Stephan Achenbach, Ronny R Buechel, Thor Edvardsen, Marco Francone, Oliver Gaemperli, Marcus Hacker, Fabien Hyafil, Philipp A Kaufmann, Patrizio Lancellotti, Koen Nieman, Gianluca Pontone, Francesca Pugliese, Hein J Verberne, Matthias Gutberlet, Jeroen J Bax, Danilo Neglia, Bernhard Gerber, Erwan Donal, Frank Flachskampf, Kristina Haugaa, Victoria Delgado, Juhani Knuuti, Paul Knaapen, Pal Maurovich-Horvat, Stephen Schroeder

    Introduction

    更新日期:2017-11-17
  • Leucocyte immunoglobulin-like receptor subfamily-B5 (LILRB5) genetic variation and statin-associated muscle symptoms: another piece in a puzzling puzzle
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-20
    Winfried März, Ulrich Laufs

    This editorial refers to ‘A common missense variant of LILRB5 is associated with statin intolerance and myalgia’, by M.K. Siddiqui et al., doi: 10.1093/eurheartj/ehx467.

    更新日期:2017-11-17
  • Additional value of native T1 mapping in tissue characterization of cardiac aspergillosis
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-20
    Davide Curione, Paolo Ciliberti, Teresa Santangelo, Aurelio Secinaro

    A 10-year-old girl, affected by acute myeloid leukaemia who developed pulmonary aspergillosis after bone marrow transplant, underwent a contrast-enhanced chest computed tomography. The scan showed bilateral pulmonary consolidations and left pleural effusion, consistent with the known infection. In the delayed post-contrast acquisitions, two ring-enhancing lesions with a hypodense central core were also noted within the left ventricular myocardium, at the mid-apical antero-lateral and inferior walls, respectively (Panel A, arrows). After 2 weeks of antifungal treatment, a cardiac magnetic resonance imaging scan was performed for further myocardial lesions characterization. The functional and morphologic sequences acquired before contrast administration showed mild to no myocardial abnormalities; in particular, a faint hyperintensity of the inferior wall on black-blood fat-saturated T2-weighted images (Panel B, dashed circle) was noted....

    更新日期:2017-11-17
  • Cardiomyopathy in Friedreich’s Ataxia
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-20
    Pablo Salazar, Raksha Indorkar, Michael Dietrich, Afshin Farzaneh-Far

    A 27-year old man with Friedreich’s Ataxia was referred for cardiac evaluation. He had no cardiac symptoms, and his physical exam was remarkable for an ataxic-gait and increased muscle tone. He was diagnosed with Friedreich’s Ataxia at the age of 18 with genetic testing showing homozygous GAA expansions in the frataxin gene. His electrocardiogram was remarkable for inferolateral Q waves (PanelA). Cardiac magnetic resonance (CMR) cine imaging showed an ejection fraction of 45% with mild asymmetric septal hypertrophy (PanelsB and C, Supplementary material online, Videos S1 and S2). Late gadolinium enhancement imaging demonstrated septal mid-myocardial and patchy lateral hyperenhancement (PanelsD and E). Cardiac magnetic resonance feature-tracking demonstrated reduced global longitudinal strain (−11%) and diminished regional longitudinal strain particularly in...

    更新日期:2017-11-17
  • A new staging system for cardiac transthyretin amyloidosis
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-18
    Julian D Gillmore, Thibaud Damy, Marianna Fontana, Matthew Hutchinson, Helen J Lachmann, Ana Martinez-Naharro, Candida C Quarta, Tamer Rezk, Carol J Whelan, Esther Gonzalez-Lopez, Thirusha Lane, Janet A Gilbertson, Dorota Rowczenio, Aviva Petrie, Philip N Hawkins

    Cardiac transthyretin (ATTR) amyloidosis is an increasingly recognized, progressive, and fatal cardiomyopathy, the natural history of which remains unclear. We sought to establish and validate a new prognostic staging system applicable to patients with both wild-type ATTR (ATTRwt) and hereditary variant ATTR (ATTRv) amyloid cardiomyopathy.

    更新日期:2017-11-17
  • Coronary optical coherence tomography-derived virtual fractional flow reserve (FFR): anatomy and physiology all-in-one
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-17
    Eric K W Poon, Vikas Thondapu, Eve Revalor, Andrew Ooi, Peter Barlis

    Most invasive coronary imaging modalities only provide anatomical information from which physiologic significance is inferred. Fractional flow reserve (FFR) and other physiologic indices of lesion severity are more reliable methods to identify physiologically significant lesions. Currently, accomplishing both anatomic and physiologic interrogation of an intermediate coronary stenosis requires the use of multiple devices within the coronary artery.

    更新日期:2017-11-17
  • CD27 co-stimulation increases the abundance of regulatory T cells and reduces atherosclerosis in hyperlipidaemic mice
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-16
    Holger Winkels, Svenja Meiler, Dirk Lievens, David Engel, Charlotte Spitz, Christina Bürger, Linda Beckers, Angelika Dandl, Sigrid Reim, Maiwand Ahmadsei, Helene Hartwig, Lesca M. Holdt, Michael Hristov, Remco T.A. Megens, Martin M. Schmitt, Eric A. Biessen, Jannie Borst, Alexander Faussner, Christian Weber, Esther Lutgens, Norbert Gerdes

    The co-stimulatory receptor CD27 modulates responses of T cells, B cells, and NK cells. Various T cell subsets participate in atherogenesis. However, the role of CD27 in atherosclerosis remains unexplored.

    更新日期:2017-11-17
  • 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-16
    Ulf Landmesser, M John Chapman, Jane K Stock, Pierre Amarenco, Jill J F Belch, Jan Borén, Michel Farnier, Brian A Ference, Stephan Gielen, Ian Graham, Diederick E Grobbee, G Kees Hovingh, Thomas F Lüscher, Massimo F Piepoli, Kausik K Ray, Erik S Stroes, Olov Wiklund, Stephan Windecker, Jose Luis Zamorano, Fausto Pinto, Lale Tokgözoğlu, Jeroen J Bax, Alberico L Catapano

    The first randomized controlled data from cardiovascular outcomes trials with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have now been reported.1,2 This ESC/EAS Task Force met to consider the impact on practical guidance for the use of these novel agents.  This updated clinical guidance provides novel clinical decision algorithms when considering a PCSK9 inhibitor, and monitoring treatment efficacy to statin, ezetimibe and PCSK9 inhibitor. Gaps in knowledge for PCSK9 inhibition are also discussed.

    更新日期:2017-11-17
  • Catecholamine crisis presenting as takotsubo cardiomyopathy caused by a 30-year old ‘Benign’ thoracic tumour
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-13
    Elisabeth Lassnig, Ahmed Hafez, Herwig Tuppy, Thomas Weber

    Case report

    更新日期:2017-11-17
  • Dilated cardiomyopathy complicated with visceral heterotaxy
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-13
    Masaki Tsuji, Eisuke Amiya, Masaru Hatano, Issei Komuro

    Case report

    更新日期:2017-11-17
  • Filamin A mitral valve disease: prolapse, dystrophy, or dysplasia?
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-12
    Gaetano Thiene, Cristina Basso

    This editorial refers to ‘New insights into mitral valve dystrophy: a Filamin-A genotype–phenotype and outcome study’, by Le Tourneau T et al., doi: 10.1093/eurheartj/ehx505.

    更新日期:2017-11-17
  • Advancing precision medicine for the treatment of long-QT syndrome type 2: shedding light on lumacaftor
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-11
    Brian P Delisle, Craig T January

    This editorial refers to ‘Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model’, by A. Mehta et al., doi: 10.1093/eurheartj/ehx394.

    更新日期:2017-11-17
  • Improving Cardiovascular Risk Prediction: A Tale of Sisyphus
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-10
    Marc L De Buyzere, Thierry C Gillebert

    This editorial refers to ‘Office blood pressure or ambulatory blood pressure for the prediction of cardiovascular events’, by R.N. Mortensen et al., doi: 10.1093/eurheartj/ehx464.

    更新日期:2017-11-17
  • Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-10
    John G F Cleland, Karina V Bunting, Marcus D Flather, Douglas G Altman, Jane Holmes, Andrew J S Coats, Luis Manzano, John J V McMurray, Frank Ruschitzka, Dirk J van Veldhuisen, Thomas G von Lueder, Michael Böhm, Bert Andersson, John Kjekshus, Milton Packer, Alan S Rigby, Giuseppe Rosano, Hans Wedel, Åke Hjalmarson, John Wikstrand, Dipak Kotecha

    Recent guidelines recommend that patients with heart failure and left ventricular ejection fraction (LVEF) 40–49% should be managed similar to LVEF ≥ 50%. We investigated the effect of beta-blockers according to LVEF in double-blind, randomized, placebo-controlled trials.

    更新日期:2017-11-17
  • Clinical genetics and outcome of left ventricular non-compaction cardiomyopathy
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-06
    Farbod Sedaghat-Hamedani, Jan Haas, Feng Zhu, Christian Geier, Elham Kayvanpour, Martin Liss, Alan Lai, Karen Frese, Regina Pribe-Wolferts, Ali Amr, Daniel Tian Li, Omid Shirvani Samani, Avisha Carstensen, Diana Martins Bordalo, Marion Müller, Christine Fischer, Jing Shao, Jing Wang, Ming Nie, Li Yuan, Sabine Haßfeld, Christine Schwartz, Min Zhou, Zihua Zhou, Yanwen Shu, Min Wang, Kai Huang, Qiutang Zeng, Longxian Cheng, Tobias Fehlmann, Philipp Ehlermann, Andreas Keller, Christoph Dieterich, Katrin Streckfuß-Bömeke, Yuhua Liao, Michael Gotthardt, Hugo A Katus, Benjamin Meder

    In this study, we aimed to clinically and genetically characterize LVNC patients and investigate the prevalence of variants in known and novel LVNC disease genes.

    更新日期:2017-11-17
  • Targeted antiplatelet therapy: novel treatment options for ischaemic heart disease
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-06
    Meinrad Gawaz, Oliver Borst

    This editorial refers to ‘A single-chain antibody-CD39 fusion protein targeting activated platelets protects from cardiac ischaemia/reperfusion injury’ by M. Ziegler et al., doi: 10.1093/eurheartj/ehx218.

    更新日期:2017-11-17
  • Inter-ethnic differences in valve morphology, valvular dysfunction, and aortopathy between Asian and European patients with bicuspid aortic valve
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-06
    William K F Kong, Madelien V Regeer, Kian K Poh, James W Yip, Philippe J van Rosendael, Tiong C Yeo, Edgar Tay, Vasileios Kamperidis, Enno T van der Velde, Bart Mertens, Nina Ajmone Marsan, Victoria Delgado, Jeroen J Bax

    Transcatheter aortic valve replacement (TAVR) has been shown safe and feasible in patients with bicuspid aortic valve (BAV) morphology. Evaluation of inter-ethnic differences in valve morphology and function and aortic root dimensions in patients with BAV is important for the worldwide spread of this therapy in this subgroup of patients. Comparisons between large European and Asian cohorts of patients with BAV have not been performed, and potential differences between populations may have important implications for TAVR.

    更新日期:2017-11-17
  • Detecting myocardial infarction type 2: targetting the right patients
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-05
    Kristian Thygesen, Allan S Jaffe

    This editorial refers to ‘Discrimination of patients with type 2 myocardial infarction’, by J.T. Neumann et al., doi: 10.1093/eurheartj/ehx457.

    更新日期:2017-11-17
  • Corrigendum
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-05

    Corrigendum to: Global position paper on cardiovascular regenerative medicine [Eur Heart J (2017); 38(33): 2532–2546].

    更新日期:2017-11-17
  • Corrigendum
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-04

    Corrigendum to: Adenoviral intramyocardial VEGF-DΔNΔC gene transfer increases myocardial perfusion reserve in refractory angina patients: a phase I/IIa study with 1-year follow-up [Eur Heart J (2017); 38(33): 2547–2555]

    更新日期:2017-11-17
  • Anticoagulation combined with antiplatelet therapy in patients with left ventricular thrombus after first acute myocardial infarction
    Eur. Heart J. (IF 19.651) Pub Date : 2017-10-03
    Naoki Maniwa, Masashi Fujino, Michikazu Nakai, Kunihiro Nishimura, Yoshihiro Miyamoto, Yu Kataoka, Yasuhide Asaumi, Yoshio Tahara, Michio Nakanishi, Toshihisa Anzai, Kengo Kusano, Takashi Akasaka, Yoichi Goto, Teruo Noguchi, Satoshi Yasuda

    There are limited data about the optimal anti-thrombotic therapy for preventing embolism while minimizing bleeding events in patients with first acute myocardial infarction (AMI) complicated by left ventricular thrombus (LVT).

    更新日期:2017-11-17
Some contents have been Reproduced with permission of the American Chemical Society.
Some contents have been Reproduced by permission of The Royal Society of Chemistry.
化学 · 材料 期刊列表